Inhibition of cytokine-induced SH2 protein in NK cells
US11104735B2 · kind B2 · utility
3Cited by
0References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 9, 2020 |
| Grant date | Aug 31, 2021 |
| Priority date | — |
| Expiry date | Dec 9, 2040 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to therapeutic and prophylactic methods based on inhibition of CIS in NK cells. In particular, the present invention relates to treating or preventing a NK-responsive condition by administering to a subject a CIS inhibitor, or administering CIS-inhibited NK cells. The invention further relates to methods for identifying a CIS inhibitor, and for determining a likelihood of cancer response to treatment with CIS inhibition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.